Adicet Bio’s ADI-001 Gains FDA Fast Track for Lupus Nephritis

Adicet Bio (ACET) has issued an update.

Adicet Bio, Inc. has announced that their innovative therapy, ADI-001, has been granted Fast Track Designation by the FDA for the treatment of Lupus Nephritis. This significant development could potentially accelerate the approval process and bring this new treatment to patients sooner, signaling a promising advancement in the fight against this challenging autoimmune disease.

For an in-depth examination of ACET stock, go to TipRanks’ Stock Analysis page.